Reports Q3 R&D expenses $30.5M and G&A expenses $8.3M. Cash, cash equivalents, and marketable securities were $171.1M as of September 30. Including an initial $25M drawn from a new loan facility in November, the company expects to have a cash runway into 2027. “Kyverna’s execution across significant clinical and corporate milestones provides us with strong momentum heading into the new year,” said Warner Biddle, CEO of Kyverna Therapeutics (KYTX).
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KYTX:
- KYTX Earnings this Week: How Will it Perform?
- Kyverna Therapeutics Secures $150 Million Loan Facility
- Kyverna Therapeutics secures up to $150M in non-dilutive financing
- 3 Best Stocks to Buy Now, 10/30/2025, According to Top Analysts
- Promising Phase 2 Data and Favorable Safety Profile Drive Buy Rating for Kyverna Therapeutics’ KYV-101